According to research reviewed by Gram, a 2026 retrospective study of 150 treated patients found that changes in insulin resistance could not be clearly linked to changes in recorded systolic blood pressure. The estimate was 2.20 mmHg per doubling of insulin resistance, with a range from -1.90 to 6.31, so the result remains uncertain.
A new 2026 study asked a common question: when people with metabolic problems take medicine, does improving insulin resistance also lower blood pressure? According to research reviewed by Gram, the answer from this retrospective review of 150 patients is still unclear. Researchers estimated that each doubling of insulin resistance, measured by a score called HOMA-IR, was linked to a 2.20 mmHg rise in systolic, or top-number, blood pressure. However, the result was not statistically reliable, because the possible range included zero. Blood pressure did fall across treatment groups, but those differences were also uncertain. The team also found that most recorded readings were rounded to multiples of 5, and that missing details about medicine use, adherence, and visit timing made the picture hard to read. The study’s main value is showing why routine medical records often cannot support firm conclusions.
Key Statistics
A 2026 retrospective cohort of 150 treated patients estimated that each doubling of insulin resistance (HOMA-IR) was associated with a 2.20 mmHg rise in systolic blood pressure, but the 95% confidence interval ran from -1.90 to 6.31 mmHg, leaving the link uncertain.
In that 2026 study, 720 of 724 recorded blood pressure values (about 99 percent) were multiples of 5 mmHg, suggesting that routine readings were often rounded.
The Quick Take
- What they studied: Researchers wanted to know whether changes in insulin resistance, a measure of how well the body uses insulin, went along with changes in systolic blood pressure in people already receiving treatment.
- Who participated: 150 adults treated in an internal medicine setting, with 132 hospital inpatients and 18 outpatients at the start. Each person had visits labeled baseline, month 3, and month 6, but exact visit dates were not available.
- Key finding: A doubling of insulin resistance was linked to a 2.20 mmHg rise in blood pressure, but the possible range was -1.90 to 6.31 mmHg, which includes no effect. The result is too uncertain to draw a firm conclusion.
- What it means for you: Insulin resistance and blood pressure may be connected, but this study cannot confirm it. If you are managing either one, keep following your doctor’s plan and ask about your own numbers rather than relying on general findings.
The Research Details
This was a retrospective cohort study, meaning the researchers looked back at existing medical records instead of enrolling people and assigning them treatments. The patients were grouped by the type of management plan they had been prescribed at the start, such as medicine or diet and omega-3 supplements. Because the groups were not randomly assigned, differences between them could reflect other factors.
The team measured insulin resistance using a calculated score called HOMA-IR, which estimates how well the body responds to insulin using fasting blood sugar and insulin levels. They then compared changes in this score with changes in systolic blood pressure, the top number in a blood pressure reading. Some analyses left out participants with insulin records that could distort the score, which reduced the group to 99 people for the main analysis.
The researchers also checked how strongly results depended on specific assumptions, such as whether participants had diabetes recorded at the start or took glucose-lowering medication. Records did not show whether patients actually took their prescribed medicines or followed their diets, so the study could only describe what was prescribed, not what was done.
The study is transparent about its limits, and the authors did not overstate their findings. The sample is small, the visit timing was approximate, and key information about medication adherence was missing. Many estimates had wide ranges that crossed zero, which means they were not statistically clear. Readers should treat this as a careful look at data quality and a starting point for better research, not as a final answer.
What the Results Show
The main analysis linked each doubling of HOMA-IR to a 2.20 mmHg increase in systolic blood pressure. However, the 95% confidence interval ran from -1.90 to 6.31 mmHg. In plain terms, the data are consistent with a small rise, no change, or even a small fall, so the study could not confirm an association.
Blood pressure readings did drop by between 2.07 and 8.23 mmHg across the different prescribed management groups. Yet after statistical adjustment, the differences between groups were uncertain, with an overall p-value of 0.743, which means the evidence for a true difference was weak.
When the researchers narrowed the analysis to people without recorded diabetes or without glucose-lowering medicine, the estimates were still imprecise. The waist-to-blood-pressure relationship also did not pass the study’s statistical threshold for reliability (q = 0.107), so it could not be considered a dependable finding.
One notable observation was about how blood pressure numbers were recorded. Of 724 recorded blood pressure values, 720 (about 99 percent) were multiples of 5 mmHg, such as 120 or 130. Real measurements rarely fall this neatly on round numbers, so this pattern suggests rounding or estimation in routine records. That matters because small real changes can be hidden by rounding, and it makes it harder to tell whether treatments are working.
The study also could not evaluate whether prescribed diets or omega-3 supplements lowered blood pressure, because records did not show whether people actually followed these plans.
Many studies have reported that insulin resistance and blood pressure tend to rise and fall together, and that improving insulin sensitivity is often part of managing cardiovascular risk. This study does not contradict that broader body of work. Instead, it highlights that real-world clinical records may be too incomplete to show these links clearly when patients are already on treatment. Larger, prospective studies with better medication tracking and standardized blood pressure measurements are needed to settle the question.
The study had a small sample, and the main analysis included only 99 of the 150 patients. Visit dates were not exact, and records did not show whether people took their medicine or followed their diets. Treatment groups were not randomly assigned, so differences between them may reflect other factors. Blood pressure values were often rounded, which can blur small changes. Finally, many results were statistically uncertain, so the findings should be seen as exploratory rather than conclusive.
The Bottom Line
Based on this study alone, there is low confidence that changes in insulin resistance can be reliably linked to changes in systolic blood pressure in treated patients. The study does not show that prescribed diets or omega-3 supplements lower blood pressure. Patients and clinicians should continue to rely on established guidelines and on careful, consistent measurement, while recognizing that routine records have real limitations. Confidence is low because the findings are imprecise and the design cannot prove cause and effect.
Clinicians, researchers, and health system teams who rely on routine records to judge treatment progress should pay close attention, since the study highlights gaps in medication, adherence, and measurement data. Adults with insulin resistance, prediabetes, or high blood pressure may find it useful as a reminder to discuss their own numbers with a doctor. People without these conditions should not change their care based on this study alone.
This study followed patients over about six months, labeled as baseline, month 3, and month 6. Changes in blood pressure and insulin resistance can take several weeks to months to appear, depending on the treatment and the person. Because the findings here were uncertain, the study does not provide a reliable timeline for expecting benefits.
Frequently Asked Questions
Does insulin resistance cause higher blood pressure?
A 2026 study of 150 treated patients could not confirm a clear link. The estimated rise was 2.20 mmHg per doubling of insulin resistance, but the range of -1.90 to 6.31 mmHg included no effect, so the association remains uncertain and cause and effect cannot be established.
Can omega-3 supplements or a special diet lower blood pressure, according to recent research?
This study could not determine whether prescribed diets or omega-3 supplements worked, because records did not show whether patients followed them. Blood pressure fell by 2.07 to 8.23 mmHg across treatment groups, but those differences were not statistically clear (global p = 0.743).
Why do blood pressure readings in medical records so often end in 0 or 5?
In a 2026 study of 724 recorded readings, 720 were multiples of 5 mmHg. This pattern usually reflects rounding or estimation during routine care, which can hide small real changes and make it harder to judge whether a treatment is working.
What makes it hard to track insulin resistance and blood pressure in people already on treatment?
Incomplete records of medication use, adherence, visit timing, and measurement conditions limit interpretation. In this study of 150 patients, exact visit dates were unavailable, so trends across baseline, month 3, and month 6 were difficult to read reliably.
Want to Apply This Research?
- Record your blood pressure at the same time of day, seated and rested for five minutes, with two readings taken one minute apart, and log the exact values, including non-round numbers. Note your medication doses and whether you took them, along with the date of each reading. Consistent, precise logs make trends easier to read than occasional rounded estimates.
- Set a daily reminder to take your prescribed medicines and to log them in the app, and add a weekly check-in for any diet or supplement changes you have discussed with your doctor. Tracking adherence alongside your numbers helps you and your care team understand what is actually working.
- Over the long term, track blood pressure and any lab-based insulin resistance results on a regular schedule agreed with your clinician, ideally every few months. Review trends monthly rather than reacting to single readings, and share exported logs with your doctor during visits. If you notice persistent changes, discuss them with your care team rather than adjusting treatment on your own.
This article summarizes an exploratory retrospective study and is for general education only. It is not medical advice and does not replace guidance from your doctor or healthcare team. Do not start, stop, or change any medication, supplement, or diet based on this research without speaking to a qualified clinician who knows your health history.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.